A placebo-controlled, single-blind, crossover study to assess the effects of New Zealand pine bark extract (Enzogenol®) on glycaemic responses in healthy participants
Not Applicable
Completed
- Conditions
- DysglycaemiaGlycaemic controlDiabetesDiet and Nutrition - Other diet and nutrition disordersMetabolic and Endocrine - Diabetes
- Registration Number
- ACTRN12619001571167
- Lead Sponsor
- Massey University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
• 18-40 years of age
• BMI 18.5-25.0 kg/ m2
• HbA1c < 40 mmol/ mol
• Fasting glucose < 5.5 mmol/ L
• Not taking any medications that include blood glucose/ sugar lowering prescriptions
• Not pregnant or breastfeeding
• Not allergic to pine bark extract
• Non-smoker
• Generally healthy and not suffering from chronic diseases or diabetes
• Able to communicate well in English
Exclusion Criteria
Participants were excluded from the study if they had any form of cardiovascular, metabolic diseases, digestive ailments, if they smoked, were pregnant or lactating, and if they had any known allergies to pine bark extract or were taking medications or health supplements that would influence glycaemia.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Capillary blood samples were obtained via finger prick with a single use disposable lancet (Accu-Chek Safe T-Pro Plus) twenty minutes before the commencement of OGTT, and again at 0, 15, 30, 45, 60, 90, and 120 min during the OGTT. Blood glucose levels were immediately measured using a glucose meter (MediSense, Optium, Abbott, 2.7-4.0% CV). Incremental area under the curve of postprandial glucose was then calculated.[-20, 0, 15, 30, 45, 60, 90 and 120 min during the OGTT.]
- Secondary Outcome Measures
Name Time Method il[Nil]